Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

Not Recruiting

Trial ID: NCT01953601


This study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants are randomized to receive placebo, or 12 mg or 40 mg verubecestat, once daily. The primary study hypothesis for Part 1 is that ≥1 verubecestat dose is superior to placebo with respect to the change from baseline in the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score at 104 weeks. Participants completing Part 1 may choose to participate in Part 2, which is a long term double-blind extension to assess efficacy and safety of verubecestat administered for up to an additional 260 weeks. In Part 2, all participants receive either 12 mg or 40 mg verubecestat, once daily.

Official Title

A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)

Stanford Investigator(s)

Sharon Sha, MD, MS
Sharon Sha, MD, MS

Clinical Professor, Neurology & Neurological Sciences


Inclusion Criteria:

   1. Diagnosis of prodromal AD, including the following:

      1. History of subjective memory decline with gradual onset and slow progression for
      at least one year corroborated by an informant,

      2. Objective impairment in episodic memory by memory test performed at Screening,

      3. Does not meet criteria for dementia, AND

      4. Positive Screening amyloid imaging PET scan using [18F]flutametamol tracer or
      positive Screening CSF tau:amyloid-β42 (Aβ42) ratio (Participants with a prior
      positive amyloid imaging PET scan or a Screening PET scan with florbetaben or
      florbetapir may be enrolled without a Screening flutemetamol scan with Sponsor

   2. Able to read at a 6th grade level or equivalent

   3. If participant is receiving an acetylcholinesterase inhibitor or memantine, the dose
   must have been stable for at least three months before Screening

   4. Must have a reliable and competent trial partner/informant who has a close
   relationship with the participant and is willing to accompany the participant to all
   required trial visits, and to monitor compliance of the administration of the trial

Inclusion Criteria for Extension Period (Part 2):

   1. Tolerated study drug and completed the initial 104-week period of the trial (Part 1)

   2. Participant must have a reliable and competent trial partner who must have a close
   relationship with the subject

Exclusion Criteria:

   1. History of stroke

   2. Evidence of a clinically relevant neurological disorder other than the disease being
   studied (i.e., prodromal AD)

   3. History of seizures or epilepsy within the last 5 years

   4. Evidence of a clinically relevant or unstable psychiatric disorder, excluding major
   depression in remission

   5. Participant is at imminent risk of self-harm or of harm to others

   6. History of alcoholism or drug dependency/abuse within the last 5 years before

   7. Participant does not have a magnetic resonance imaging (MRI) scan obtained within 12
   months of Screening and is unwilling or not eligible to undergo an MRI scan at the
   Screening Visit. With Sponsor approval, a head computed tomography (CT) scan may be
   substituted for MRI scan to evaluate eligibility

   8. History of hepatitis or liver disease that has been active within the 6 months prior
   to Screening

   9. Recent or ongoing, uncontrolled, clinically significant medical condition within 3
   months of Screening

10. History of malignancy occurring within the 5 years before Screening, except for
   adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
   or localized prostate carcinoma

11. Clinically significant vitamin B12 or folate deficiency in the 6 months before

12. Use of any investigational drugs or participation in clinical trials within the 30
   days before Screening

13. History of a hypersensitivity reaction to more than three drugs

14. Has human immunodeficiency virus (HIV) by medical history

15. Participant is unwilling or has a contraindication to undergo PET scanning including
   but not limited to claustrophobia, excessive weight or girth

16. History or current evidence of long QT syndrome, corrected QT (QTc) interval ≥470
   milliseconds (for male participants) or ≥480 milliseconds (for female participants),
   or torsades de pointes

17. Close family member (including the trial partner, spouse or children) who is among the
   personnel of the investigational or sponsor staff directly involved with this trial

Exclusion Criteria for Extension Period (Part 2):

   1. Participant is at imminent risk of self-harm or of harm to others

   2. Has developed a recent or ongoing, uncontrolled, clinically significant medical or
   psychiatric condition

   3. Results of safety assessments (e.g., laboratory tests) performed in participant at end
   of Part 1 that are clinically unacceptable to the Investigator

   4. Has developed a form of dementia that is not AD

   5. Has progressed to dementia due to AD per investigator diagnosis in the initial
   104-week study (Part 1).

Exclusion Criteria for NFT PET Substudy (Part 2):

1. Had one or two PET scans with MK-6240 in the initial 104-week study.


drug: Verubecestat 12 mg (Parts 1 and 2)

drug: Verubecestat 40 mg (Parts 1 and 2)

other: Placebo (Part 1)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jennifer Gaudioso